Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-ASGR1 Antibody-FITC (3Z697)
😃Good
Catalog No. TMAY-01149F
Alias HL-1, CLEC4H1, asialoglycoprotein receptor 1, ASGPR1, ASGPR
Anti-ASGR1 Antibody-FITC (3Z697) is a FITC-conjugated Mouse antibody targeting ASGR1. Anti-ASGR1 Antibody-FITC (3Z697) can be used in FCM.
Anti-ASGR1 Antibody-FITC (3Z697)
Anti-ASGR1 Antibody-FITC (3Z697)
😃Good
Catalog No. TMAY-01149FAlias HL-1, CLEC4H1, asialoglycoprotein receptor 1, ASGPR1, ASGPR
Anti-ASGR1 Antibody-FITC (3Z697) is a FITC-conjugated Mouse antibody targeting ASGR1. Anti-ASGR1 Antibody-FITC (3Z697) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 T | $80 | 7-10 days | |
| 100 T | $176 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Antibody Type: Mouse Monoclonal Application: FCM Reactivity: Human |
| Alias | HL-1, CLEC4H1, asialoglycoprotein receptor 1, ASGPR1, ASGPR |
| Ig Type | Mouse IgG1 |
| Clone | 3Z697 |
| Reactivity | Human |
| Verified Activity | Flow cytometric analysis of Human Asialoglycoprotein Receptor expression on HepG2 cells. Cells were stained with FITC-conjugated anti-Human Asialoglycoprotein Receptor. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Application | FCM |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ASGPR1 / ASGR1 (rh ASGPR1 / ASGR1; TMPY-02702; P07306; Gln62-Leu291) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). ASGPR belongs to the long-form subfamily of the C-type/Ca2+ dependent lectin family. It is a complex of two noncovalently-linked and highly homologous subunits, a major 42 kDa glycoprotein ASGPR1(MHL-1) and a minor 51 kDa glycoprotein ASGR2 (MHL-2). ASGPR1 is synthesized as a type II transmembrane protein that contains a cytosolic N-terminal domain, a single transmembrane segment, and an extracellular domain which contains two important structural regions. The first is a stalk domain that contributes to noncovalent oligomerization, and the second is a Ca2+-dependent carbohydrate binding domain at the very C-terminus that is unusually stabilized by three ions. The research regarded that ASGPR1 could be targeted for anti- hepatitis B virus (HBV) drug development. |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human ASGPR1 / ASGR1 Protein (TMPY-02702) |
| Antigen Species | Human |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-ASGR1 Antibody-FITC (3Z697) | purchase Anti-ASGR1 Antibody-FITC (3Z697) | Anti-ASGR1 Antibody-FITC (3Z697) cost | order Anti-ASGR1 Antibody-FITC (3Z697)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.